Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Shares Acquired by ADAR1 Capital Management LLC

ADAR1 Capital Management LLC boosted its stake in shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) by 196.5% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 169,505 shares of the company’s stock after purchasing an additional 112,339 shares during the quarter. ADAR1 Capital Management LLC’s holdings in Lexeo Therapeutics were worth $1,115,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in LXEO. Frazier Life Sciences Management L.P. bought a new stake in Lexeo Therapeutics in the third quarter worth approximately $11,307,000. Point72 Asset Management L.P. bought a new stake in Lexeo Therapeutics during the 3rd quarter valued at approximately $3,348,000. Geode Capital Management LLC grew its stake in shares of Lexeo Therapeutics by 86.5% in the third quarter. Geode Capital Management LLC now owns 553,247 shares of the company’s stock worth $5,003,000 after acquiring an additional 256,635 shares during the last quarter. Privium Fund Management B.V. bought a new position in shares of Lexeo Therapeutics during the 4th quarter worth about $909,000. Finally, Exome Asset Management LLC acquired a new position in Lexeo Therapeutics in the 3rd quarter valued at approximately $797,000. Hedge funds and other institutional investors own 60.67% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on LXEO shares. HC Wainwright reiterated a “buy” rating and issued a $23.00 price objective on shares of Lexeo Therapeutics in a research note on Wednesday, March 26th. Chardan Capital reiterated a “buy” rating and issued a $25.00 price objective on shares of Lexeo Therapeutics in a research report on Tuesday, March 25th. Royal Bank of Canada dropped their price objective on Lexeo Therapeutics from $24.00 to $20.00 and set an “outperform” rating for the company in a report on Tuesday, March 25th. Finally, Leerink Partners cut their price target on Lexeo Therapeutics from $19.00 to $18.00 and set an “outperform” rating on the stock in a research note on Monday, March 24th. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Lexeo Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $22.80.

Lexeo Therapeutics Price Performance

Shares of NASDAQ LXEO opened at $2.34 on Monday. The company has a current ratio of 5.95, a quick ratio of 5.95 and a debt-to-equity ratio of 0.01. The firm has a market cap of $77.68 million, a P/E ratio of -0.74 and a beta of 1.52. The business’s 50 day moving average is $3.82 and its 200-day moving average is $6.29. Lexeo Therapeutics, Inc. has a 1-year low of $2.27 and a 1-year high of $19.50.

Lexeo Therapeutics (NASDAQ:LXEO) last announced its quarterly earnings data on Monday, March 24th. The company reported ($0.78) EPS for the quarter, beating the consensus estimate of ($0.87) by $0.09. Equities research analysts predict that Lexeo Therapeutics, Inc. will post -3.14 earnings per share for the current year.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.